Observational studyFrontiers in immunology
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial.
Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Frontiers in immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- COVID-19 vaccination effectiveness and safety in vulnerable populations: a meta-analysis of 33 observational studies.Frontiers in pharmacology · 2023Pooled it
- COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis.Multiple sclerosis and related disorders · 2022Pooled it
- A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.International immunopharmacology · 2022Pooled it
- Article
- An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.Pathogens (Basel, Switzerland) · 2025Review
- Updated Considerations for the Immunopharmacological Aspects of the "Talented mRNA Vaccines".Vaccines · 2023Review
- Article
- COVID-19 vaccines and a perspective on Africa.Trends in immunology · 2023Review
- Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.Frontiers in oncology · 2023Article
- COVID-19 in children and adolescents with neuroimmunological disorders.Clinics (Sao Paulo, Brazil) · 2023Article
- Medical Residents' Behaviours toward Compulsory COVID-19 Vaccination in a Tertiary Hospital in Italy.International journal of environmental research and public health · 2022Article
- Evaluation of Immunogenicity to Three Doses of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Lung Transplant Patients.Vaccines · 2022Article
- Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection.Medicina (Kaunas, Lithuania) · 2022Article
- A Comprehensive Review of Neuromuscular Manifestations of COVID-19 and Management of Pre-Existing Neuromuscular Disorders in Children.Journal of clinical medicine · 2022Review
- Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study.Frontiers in oncology · 2022Article
- Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare.Frontiers in oncology · 2022Article
- mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients.Frontiers in oncology · 2022Article
- Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19. The COMETA Italian Protocol.Frontiers in oncology · 2022Article
- What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?EBioMedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 14 institutions in 2 countries.
Chiara AgratiCellular Immunology Laboratory, Department of Epidemiology, Preclinical Research and Advanced Diagnostic, National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani - IRCCS, Roma, Italy.
Serena Di CosimoBiomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Daniela FenoglioDepartment of Internal Medicine and Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.
Giovanni ApoloneScientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Fabio CiceriScientific Directorate, IRCSS San Raffaele Scientific Institute, Milano, Italy.
Gennaro CilibertoIRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.
Fausto BaldantiMolecular Virology Unit, Fondazione IRCCS Policlinico San Matteo; Dpt. of Clinical, Surgical, Diagnostics and Pediatric Sciences, University of Pavia, Pavia, Italy.
Massimo CostantiniScientific Directorate, Azienda Unita Sanitaria Locale (USL)-IRCCS Reggio Emilia, Reggio Emilia, Italy.
Diana GiannarelliBiostatistical Unit, Istituto Nazionale Tumori Regina Elena IRCCS - IFO, Rome, Italy.
Giuseppe IppolitoScientific Directorate, INMI Lazzaro Spallanzani - IRCCS, Roma, Italy.
Franco LocatelliDepartment of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Department of Gynecology-Obstetrics and Pediatrics, University "La Sapienza", Roma, Italy.
Alberto MantovaniScientific Directorate, IRCCS Humanitas Clinical and Research Center, Rozzano, Italy.
Aldo MorroneScientific Directorate, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
Fabrizio TagliaviniScientific Directorate, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Antonio UccelliDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy.
Pier Luigi ZinzaniIRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Nicola SilvestrisMedical Oncology Department, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Maria RescignoDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITBambino Gesù Children's Hospital · ITFondazione IRCCS Istituto Neurologico Carlo Besta · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITIstituto Tumori Bari · ITOspedale Policlinico San Martino · ITPoliclinico San Matteo Fondazione · ITSan Gallicano Hospital · ITUniversity of Bologna · ITUniversity of Genoa · ITVita-Salute San Raffaele University · ITWilliam Harvey Research Institute · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients diagnosed with malignancy, neurological and immunological disorders,
Indexed as
AdultClinical ProtocolsCOVID-19 VaccinesHumansImmune System DiseasesImmunocompromised HostNeoplasmsNervous System DiseasesPatient SelectionProspective StudiesCOVID-19 VaccinescancerCOVID-19immunocompromisedmyastheniaSARS-CoV-2vaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.